Literature DB >> 15049794

The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation.

Nitika Arora-Gupta1, Paul Davies, Patrick McKiernan, Deirdre A Kelly.   

Abstract

Calcineurin inhibitor drugs (CNI), cyclosporin and tacrolimus are potent immunosuppressants, which have improved survival after liver transplantation. We evaluated long-term renal function in children receiving calcineurin inhibitors after liver transplantation. A retrospective analysis of all children undergoing orthotopic liver transplantation (OLT) from 1989 to 1999 who survived 1-yr post-transplantation was performed. All received prednisolone and either cyclosporin and azathioprine or tacrolimus. Steroids were withdrawn at 3 months and cyclosporin/tacrolimus monotherapy was initiated 12 months post-OLT. Calculated glomerular filtration rate (cGFR) was calculated using the modified Counahan-Barratt formula and measured pretransplant, 3, 6 and 12 months post-transplant and annually thereafter. Data were analysed in a serial manner to evaluate the trend of cGFR over time selectively using the Wilcoxon signed rank test and paired t-tests as appropriate. A total of 113 patients (65 males:48 females) were followed up for more than 1 yr (maximum 5 yr). Median (range) age at transplantation was 26 months (3-177). There was a significant fall of 35% in cGFR at 3 months compared with the pretransplant value (p = 0.001). By 12 months following the reduction in immunosuppression dosage, renal function stabilized with a slight improvement in cGFR which reached 76% of the pretransplant value at 5 yr (p < 0.001). Children who were <1 yr of age at the time of OLT had better recovery of renal function than older children (p = 0.02). No association was seen with sex, the type of immunosuppression or the underlying diagnosis. Renal dysfunction is a known complication of CNI therapy. Despite an initial reduction in cGFR, which was associated with maximal immunosuppression, long-term low dose CNI therapy was not associated with continued deterioration of renal function, particularly in children who were transplanted as infants.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15049794     DOI: 10.1046/j.1399-3046.2003.00132.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  8 in total

1.  Risk factors for end-stage kidney disease after pediatric liver transplantation.

Authors:  R L Ruebner; P P Reese; M R Denburg; E B Rand; P L Abt; S L Furth
Journal:  Am J Transplant       Date:  2012-09-20       Impact factor: 8.086

Review 2.  Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.

Authors:  J Michael Tredger; Nigel W Brown; Anil Dhawan
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function.

Authors:  David C Bartlett; Carla Lloyd; Patrick J McKiernan; Phil N Newsome
Journal:  J Inherit Metab Dis       Date:  2014-02-11       Impact factor: 4.982

4.  Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients.

Authors:  Mariam H Abdel Jalil; Ahmed F Hawwa; Patrick J McKiernan; Michael D Shields; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

5.  Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant.

Authors:  Ahmed F Hawwa; Patrick J McKiernan; Michael Shields; Jeff S Millership; Paul S Collier; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

Review 6.  Adverse effects of immunosuppression in pediatric solid organ transplantation.

Authors:  Kristine S Schonder; George V Mazariegos; Robert J Weber
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

7.  Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1.

Authors:  David C Bartlett; Mary Anne Preece; Elisabeth Holme; Carla Lloyd; Phil N Newsome; Patrick J McKiernan
Journal:  J Inherit Metab Dis       Date:  2012-03-29       Impact factor: 4.982

Review 8.  Clinical transplantation and tolerance: are we there yet?

Authors:  R F Saidi; S K Hejazii Kenari
Journal:  Int J Organ Transplant Med       Date:  2014
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.